Industry News
Pharmaceutical Industry News
Biogen and Minor League…
Biogen and Minor League Baseball’s Durham Bulls are joining forces to celebrate “America 250” in the Triangle Community.
AbbVie is running a new psoriasis…
AbbVie is running a new psoriasis campaign based on feedback from real patients about how the condition affects their daily lives.
6 medicamentos comunes que pueden reducir el riesgo de demencia
Algunos estudios han descubierto que ciertos fármacos contra la inflamación, la hipertensión y otros padecimientos, podrían tener un impacto protector. Esto es lo que sabemos.
Iris Long, Scientific Mentor to AIDS Activists, Dies at 92
A chemist, she lent her expertise in drug research to ACT UP, an organization known for its street protests, and helped accelerate the approval of H.I.V. and AIDS treatments.
New Treatment Lets 3 Transplant Patients Halt Anti-Rejection Drugs
Researchers at the University of Pittsburgh gave transplant recipients certain immune cells from their organ donors. It didn’t always work.
The FDA should strengthen the…
The FDA should strengthen the evidence required for drug approvals under its accelerated pathway, and increase the transparency surrounding those regulatory decisions, too, according to a report from a prominent industry and government watchdog.
The legal back-and-forth over…
The legal back-and-forth over migraine meds from Teva and Eli Lilly has resurfaced, with Teva gaining favor on appeal after a 2023 defeat.
6 Common Medications That May Decrease Dementia Risk
Some vaccines, along with heart medications and other drugs, appear to have a protective benefit.
Astellas will close a stem cell…
Astellas will close a stem cell therapy site. GSK is pushing a Hansoh Pharma-partnered ADC into multiple phase 3 trials. Daiichi Sankyo is selling its consumer health business unit for about $1.55 billion. And more.
The Biotechnology Innovation…
The Biotechnology Innovation Organization has started the nationwide “The Fight of Our Lives” campaign, creating a video and other materials to show the stories behind biotech breakthroughs and their effects on patients.
Help for Medicare Advantage Patients Who Lose Doctors Is Shelved, for Now
Nationwide, hospitals and other providers are leaving private Medicare Advantage plans, putting thousands of seniors at risk of higher costs and of losing trusted doctors.
Batch of Anti-Anxiety Drug Xanax Recalled, F.D.A. Says
The recall affects only a small number of pills, sold nationwide under the brand name Xanax XR.
The company highlights the…
The company highlights the features of its AI-powered Verily Me app in two 30-second spots that launched across national TV, audio and social channels.
Viatris and Teva Pharmaceutical…
Viatris and Teva Pharmaceutical Industries recently launched separate recalls related to dissolution problems for a common anxiety medication and concerns around an unapproved raw material in a high blood pressure patch, respectively.
The anti-amyloid drug class has…
The anti-amyloid drug class has yielded some FDA approvals and plenty of failed candidates. Now, researchers are looking at the overall track record of the group and painting an unpleasant picture about the efficacy of
Rather than relying on patient…
Rather than relying on patient groups to make an impassioned plea, Roche aims to put doubts to rest around the controversial Duchenne muscular dystrophy gene therapy Elevidys with the rigor of another clinical study.
Eli Lilly is wasting no time in…
Eli Lilly is wasting no time in pursuit of the next indication for its newly christened obesity pill Foundayo, presenting new data in diabetes Thursday that also serves to address the FDA’s desire for more
Omnicom Health has stamped its…
Omnicom Health has stamped its mark on the recently acquired FCB Health New York, rebranding the ad agency as Olixir New York in the aftermath of the mega-merger with Interpublic Group.
Analysis of Alzheimer’s Drugs Stirs Debate About Their Effectiveness
The review said a certain class of drugs had little clinical benefit, but many Alzheimer’s experts criticized the analysis, saying it unfairly lumped failed drugs with two recently approved treatments.
GLP-1 Experimentation Is Everywhere, and Science Can’t Keep Up
Millions of Americans are experimenting with the drugs. Science can’t keep up.